Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial

BACKGROUND: In the phase 3 STELLAR trial, sotatercept, an investigational first-in-class activin signalling inhibitor, demonstrated beneficial effects on 6-min walk distance and additional efficacy endpoints in pre-treated participants with pulmonary arterial hypertension (PAH). METHODS: This post h...

Descripción completa

Detalles Bibliográficos
Autores principales: Souza, Rogerio, Badesch, David B., Ghofrani, H. Ardeschir, Gibbs, J. Simon R., Gomberg-Maitland, Mardi, McLaughlin, Vallerie V., Preston, Ioana R., Waxman, Aaron B., Grünig, Ekkehard, Kopeć, Grzegorz, Meyer, Gisela, Olsson, Karen M., Rosenkranz, Stephan, Lin, Jianxin, Johnson-Levonas, Amy O., de Oliveira Pena, Janethe, Humbert, Marc, Hoeper, Marius M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512088/
https://www.ncbi.nlm.nih.gov/pubmed/37696565
http://dx.doi.org/10.1183/13993003.01107-2023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512088/
https://www.ncbi.nlm.nih.gov/pubmed/37696565
http://dx.doi.org/10.1183/13993003.01107-2023

Ejemplares similares